These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29912407)

  • 1. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam.
    Barlow G; Morice A
    J Antimicrob Chemother; 2018 Aug; 73(8):2270-2271. PubMed ID: 29912407
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis.
    Daccò V; Claut L; Piconi S; Castellazzi L; Garbarino F; Teri A; Colombo C
    Transpl Infect Dis; 2019 Jun; 21(3):e13082. PubMed ID: 30892778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for
    Saffioti C; Barco S; Cangemi G; Mesini A; Casciaro R; Cresta F; Castellani C; Bandettini R; Morelli P; Castagnola E
    J Chemother; 2019; 31(7-8):436-438. PubMed ID: 31583970
    [No Abstract]   [Full Text] [Related]  

  • 4. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report.
    Holyk A; Belden V; Lee JJ; Musick W; Keul R; Britz GW; Lin J
    J Antimicrob Chemother; 2018 Jan; 73(1):254-256. PubMed ID: 29040635
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
    Spoletini G; Etherington C; Shaw N; Clifton IJ; Denton M; Whitaker P; Peckham DG
    J Antimicrob Chemother; 2019 May; 74(5):1425-1429. PubMed ID: 30649419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
    Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.
    Sy S; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Derendorf H
    CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):197-207. PubMed ID: 28145085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.
    Jacobs DM; DiTursi S; Ruh C; Sharma R; Claus J; Banjade R; Rao GG
    Int J Antimicrob Agents; 2016 Aug; 48(2):225-7. PubMed ID: 27396948
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a cystic fibrosis patient.
    Stokell JR; Gharaibeh RZ; Steck TR
    J Cyst Fibros; 2013 Dec; 12(6):812-6. PubMed ID: 23478130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
    Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Compatibility of Ceftazidime-Avibactam and Aztreonam Using Simulated and Actual Y-site Administration.
    O'Donnell JN; Xu A; Lodise TP
    Clin Ther; 2020 Aug; 42(8):1580-1586.e2. PubMed ID: 32684326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam.
    Los-Arcos I; Len O; Martín-Gómez MT; González-López JJ; Saéz-Giménez B; Deu M; Nuvials X; Ferrer R; Román A; Gavaldà J
    Infection; 2019 Apr; 47(2):289-292. PubMed ID: 30565008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.
    Jayol A; Nordmann P; Poirel L; Dubois V
    J Antimicrob Chemother; 2018 Feb; 73(2):542-544. PubMed ID: 29165563
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Flanagan JN; Kavanaugh L; Steck TR
    Microb Drug Resist; 2020 Jan; 26(1):1-8. PubMed ID: 31393205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.